Back to top
more

Aytu BioPharma (AYTU)

(Delayed Data from NSDQ)

$3.10 USD

3.10
5,575

+0.04 (1.31%)

Updated May 8, 2024 03:54 PM ET

After-Market: $3.15 +0.05 (1.61%) 7:54 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (90 out of 251)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Has Aytu Bioscience (AYTU) Outpaced Other Medical Stocks This Year?

Is (AYTU) Outperforming Other Medical Stocks This Year?

Aytu Bioscience, Inc. (AYTU) Reports Q3 Loss, Tops Revenue Estimates

Aytu Bioscience, Inc. (AYTU) delivered earnings and revenue surprises of 61.54% and 16.51%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Has Aytu Bioscience (AYTU) Outpaced Other Medical Stocks This Year?

Is (AYTU) Outperforming Other Medical Stocks This Year?

Aytu Bioscience Inc (AYTU) Outpaces Stock Market Gains: What You Should Know

Aytu Bioscience Inc (AYTU) closed the most recent trading day at $1.47, moving +1.38% from the previous trading session.

Aytu Bioscience, Inc. (AYTU) May Report Negative Earnings: Know the Trend Ahead of Q3 Release

Aytu Bioscience, Inc. (AYTU) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Aytu Bioscience, Inc. (AYTU) Gains As Market Dips: What You Should Know

Aytu Bioscience, Inc. (AYTU) closed at $1.64 in the latest trading session, marking a +1.23% move from the prior day.

What's in Store for Aytu BioScience's (AYTU) Q3 Earnings?

On Aytu BioScience's (AYTU) upcoming earnings call, investor focus will be on its distribution right to commercialize the COVID-19 IgG/IgM Rapid Test in North America.

Is Aytu Bioscience (AYTU) Outperforming Other Medical Stocks This Year?

Is (AYTU) Outperforming Other Medical Stocks This Year?

Aytu Bioscience, Inc. (AYTU) Stock Moves -1.27%: What You Should Know

Aytu Bioscience, Inc. (AYTU) closed at $1.55 in the latest trading session, marking a -1.27% move from the prior day.

Aytu Bioscience, Inc. (AYTU) Upgraded to Strong Buy: What Does It Mean for the Stock?

Aytu Bioscience, Inc. (AYTU) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

Aytu Bioscience, Inc. (AYTU) Stock Sinks As Market Gains: What You Should Know

Aytu Bioscience, Inc. (AYTU) closed at $1.52 in the latest trading session, marking a -1.3% move from the prior day.

Top Ranked Momentum Stocks to Buy for April 3rd

Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, April 3rd

Top Ranked Momentum Stocks to Buy for April 2nd

Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, April 2nd

Has Aytu Bioscience (AYTU) Outpaced Other Medical Stocks This Year?

Is (AYTU) Outperforming Other Medical Stocks This Year?

Aytu BioScience (AYTU) in Focus: Stock Moves 6.4% Higher

Aytu BioScience (AYTU) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.

Aytu BioScience to Issue Coronavirus Rapid Test in North America

Aytu BioScience (AYTU) expands the right to distribute and commercialize the COVID-19 IgG/IgM rapid test across the United States, Canada and Mexico. Stock jumps.

Sanghamitra Saha headshot

Coronavirus Scare Supports These Biotech ETFs & Stocks

Growing coronavirus concerns provide some support to these biotech ETFs and stocks amid a massive market sell-off.

The Zacks Analyst Blog Highlights: Danaher, Quidel, Aytu BioScience, QIAGEN and Co-Diagnostics

The Zacks Analyst Blog Highlights: Danaher, Quidel, Aytu BioScience, QIAGEN and Co-Diagnostics

Coronavirus Test Kit Demand to Drive These 3 Stocks

Point-of-care testing enables better patient triage, bed management, and patient care decisions. Here are three stocks to benefit as demand rises.

Has Aytu Bioscience (AYTU) Outpaced Other Medical Stocks This Year?

Is (AYTU) Outperforming Other Medical Stocks This Year?

Aytu BioScience, Inc. (AYTU) Shares March Higher, Can It Continue?

As of late, it has definitely been a great time to be an investor in Aytu BioScience, Inc. (AYTU).

Sanghamitra Saha headshot

Wall Street Rises on Trump's Stimulus: ETF & Stock Gainers

Trump plans to offer fiscal stimulus to counter coronavirus-related economic fallout. As the Wall Street rallied on the hopes, these ETFs and stocks gained massively.

Aytu Bioscience, Inc. (AYTU) May Report Negative Earnings: Know the Trend Ahead of Q2 Release

Aytu Bioscience, Inc. (AYTU) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Aytu Bioscience, Inc. (AYTU) Reports Q1 Loss, Lags Revenue Estimates

Aytu Bioscience, Inc. (AYTU) delivered earnings and revenue surprises of -6.67% and -0.69%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

What's in Store for Aytu BioScience's (AYTU) Q4 Earnings?

On Aytu BioScience's (AYTU) upcoming earnings call, investor focus will be on its diversified portfolio of medicines approved to treat ailments like low testosterone, insomnia and male infertility.